| MA |
Report |
Net revenue |
BEAT |
pred ~$9.18B (+12.9% y/y) vs. cons $9.068B (+11.5%) |
MEDIUM |
| MA |
Report |
Adjusted EPS |
BEAT |
pred ~$4.92 vs. cons $4.77 |
MEDIUM |
| MA |
Report |
Cross-border volume growth (local FX) |
BEAT |
pred ~14% vs. cons ~12.5% |
LOW |
| MA |
Guide |
FY26 net revenue growth (currency-neutral, ex-inorganic) |
BETTER |
guide reaffirmed/nudged to high-end low-double-digits ~13% + ~1-2ppt FX vs. cons ~12.5% (FY2026) |
MEDIUM |
| MA |
Guide |
Q3 net revenue growth / cross-border travel recovery tone |
BETTER |
guide ~13% cn (progressive recovery off Q2 trough) vs. cons ~12% (2026Q3) |
LOW |
| MA |
Guide |
VAS & Solutions cn growth |
UNCHANGED |
guide ~high-teens ~18% vs. cons ~17% (2026Q2/2H) |
MEDIUM |
| MA |
Guide |
Adjusted opex growth (cn, ex-inorganic) & tax rate |
UNCHANGED |
guide opex low-end low-double-digits ~11% and tax ~20-21% vs. cons ~11% / ~20.5% (2026Q2) |
MEDIUM |
| MA |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.8% |
— |
MEDIUM |
| MA |
Return |
5-day cumulative residual |
+0.5% (FADE) |
Beat is largely pre-negotiated (mgmt framed Q2 as the guided conflict-driven trough) and FY cn guide is already at the high end, so a modest EPS/revenue beat generates only limited upward out-period revisions. With the stock having rallied ~20% off the June low back to its highs into the print, the bar is raised; the initial pop on reassuring cross-border-recovery tone tends to fade as estimates get trimmed on the implicit soft-Q2 math and profit-taking sets in, leaving a small net-positive residual. |
LOW |